Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Status:
Terminated
Trial end date:
2016-06-24
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multi-center, Phase 2 study with Paclitaxel in combination
with Bevacizumab in patients with Unresectable or Metastatic Angiosarcoma. The study aims to
determine the safety and effectiveness of combining two drugs Paclitaxel and Bevacizumab in
the treatment of Angiosarcoma that cannot be removed by surgery, or has spread to other parts
of your body. The primary objective is to evaluate 4month non progression rate. The secondary
objective is to evaluate overall response rate after 3rd and 6th cycle, median duration of
response, 6th and 12th month survival, toxicity of Paclitaxel and Bevacizumab combination,
toxicity of maintenance Bevacizumab and to collect paraffin-embedded tumor blocks for
angiogenesis markers and tissue microarray.